Skip to main content
main-content

28.09.2016 | Retinal Disorders | Ausgabe 3/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 3/2017

Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia

Zeitschrift:
Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 3/2017
Autoren:
M. Rinaldi, F. Semeraro, F. Chiosi, A. Russo, M. R. Romano, M. C. Savastano, R. dell’Omo, C. Costagliola

Abstract

Background

To demonstrate the efficacy of intravitreal ranibizumab (IVR) in combination with reduced-fluence photodynamic therapy (RF-PDT) in patients with choroidal neovascularization (CNV) secondary to pathologic myopia.

Methods

Sixty patients affected by myopic CNV (mCNV) were randomized to receive either ranibizumab 0.5 mg monotherapy (RM; n = 20), standard fluence PDT (SF-PDT, n = 20) or RF-PDT combination therapy (n = 20). Subsequently, IVR was injected as needed. All patients were evaluated for 48 weeks.

Results

Mean BCVA change at 48 weeks was + 0.2 and +15 letters with SF or RFPDT plus ranibizumab, respectively, compared with +16.8 letters with RM. At 48 weeks, mean central foveal thickness (CFT) decrease from baseline was 58 ± 15 μm, 91.4 ± 43.8 μm, and 85 ± 41.5 μm for the verteporfin SF, RF and RM groups, respectively. Macular sensitivity improvement was + 0.4 db, + 1.9 dB and + 2.7 dB for the verteporfin SF, RF and RM groups, respectively.

Conclusions

Ranibizumab monotherapy or combined with RF-PDT improved BCVA and macular sensitivity in patients affected by mCNV, whereas CFT results were reduced. SF-PDT combination regimen mostly stabilized vision at 48 weeks. Among all groups, the RF-PDT seemed to reduce the number of ranibizumab retreatments.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 3/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

22.10.2019 | Erkrankungen der Lider | CME | Ausgabe 11/2019

Floppy-Eyelid-Syndrom

Ein häufig unterdiagnostiziertes Krankheitsbild mit interdisziplinärer Bedeutung

24.09.2019 | Der Ophthalmologe | CME | Ausgabe 10/2019

Konjunktivale Malignome

18.09.2019 | Leitthema | Ausgabe 10/2019

Toxizität von schweren Flüssigkeiten